Junzi Ke

Statistics

Publications

Citations

247

H-Index

Active since

2019

Affiliations

Guangzhou University of Chinese Medicine(Current)

ShanghaiTech University

Chinese University of Hong Kong

Junzi Ke is an author at Guangzhou University of Chinese Medicine specializing in pharmacology, cell signaling, and epithelial-mesenchymal transition in cancer.

ORCID

Publications per year

2019–2022

Publications

Fangchinoline inhibits non-small cell lung cancer metastasis by reversing epithelial-mesenchymal transition and suppressing the cytosolic ROS-related Akt-mTOR signaling pathway

Bonan Chen, Yue Song, Yujuan Zhan et al. · Cancer Letters · 2022 · 76 citations

Medicine, Oncology, Pharmacology +16

AAV-ie-K558R mediated cochlear gene therapy and hair cell regeneration

Yong Tao, Xiaoyi Liu, Yang Liu et al. · Signal Transduction and Targeted Therapy · 2022 · 69 citations · Full text

Medicine, Biotechnology, Molecular Biology +17

Blockage of Autophagic Flux and Induction of Mitochondria Fragmentation by Paroxetine Hydrochloride in Lung Cancer Cells Promotes Apoptosis via the ROS-MAPK Pathway

Kun Wang, Qing Gong, Yujuan Zhan et al. · Frontiers in Cell and Developmental Biology · 2020 · 60 citations · Full text

Life Sciences, Cell Biology, Pharmacology +17

Dioscin Inhibits the Invasion and Migration of Hepatocellular Carcinoma HepG2 Cells by Reversing TGF-β1-Induced Epithelial-Mesenchymal Transition

Bonan Chen, Shikun Zhou, Yujuan Zhan et al. · Molecules · 2019 · 42 citations · Full text

Life Sciences, Oncology, Pharmacology +15

1–4 of 4